Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 4
GLP-1 drugs and inflammation markers
A 2026 meta-analysis linked GLP-1 therapies to changes in selected inflammation and metabolic biomarkers in type 2 diabetes.
Semaglutide vs Liraglutide: Study Results
A real-world study compared semaglutide and liraglutide for later diabetes and cardiovascular outcomes, with important limits.
TB Meningitis Drug Screen: Study Results
A 2026 study tested semaglutide and other host-directed treatments for TB meningitis across mice, brain organoids and patient cells.
Zalfermin Combo Missed Its Endpoint
A phase 2 trial found no significant fibrosis benefit from adding zalfermin to semaglutide across F2 to compensated F4 MASH.
GLP-1 drugs and addiction evidence
A 2026 review found early GLP-1 and semaglutide signals in substance use disorders, but randomized evidence remains limited and mixed.
Weight Loss and Sleep-Disordered Breathing
A 2026 review explains how weight management, tirzepatide and positive airway pressure fit into care for obesity-related sleep breathing disorders.
Semaglutide and Ischemic Colitis
A 2026 oral semaglutide case report describes ischemic colitis recurring after rechallenge, a stronger signal that still cannot prove general risk.
How drug promotion shapes prescribing
A 2026 Cochrane review links pharmaceutical promotion with prescribing quality, quantity, and cost, with important limits on causality.
Semaglutide plus dapagliflozin in CKD
A short retrospective study compared semaglutide, dapagliflozin, and their combination in type 2 diabetes with chronic kidney disease.
Semaglutide Hydrogel Tested in Rats
A preclinical rat study tested a thermosensitive semaglutide hydrogel. It cannot establish human efficacy, dosing, or safety.
Semaglutide and PPGL Cells: New Data
A laboratory study found different semaglutide effects across patient-derived PPGL cultures, including a signal in three RET-linked tumors.
Semaglutide vs Resmetirom in MASH
An indirect comparison favoured semaglutide on one MASH endpoint but cannot replace a randomized head-to-head trial.